Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,469.60
(
0.64%
)
Dow Jones
49,760.56
(
0.00%
)
Brent Oil
105.51
(
-0.24%
)
Bitcoin
80,502.37
(
0.01%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: cjgaddy post# 279018

Friday, 11/18/2016 2:05:32 PM

Friday, November 18, 2016 2:05:32 PM

Post# of 347009
CJ thanks and after reading your post and the past few presentations by Dr Gray (one being with CEO Steve King) I believe we are about to witness one of the first BTDs that is 100% justified after reading the statistical significance that PS Targeting offers several other combos ..this one being anti-LAG 3+PS Targeting

http://files.shareholder.com/downloads/PPHM/1665701340x0x909638/A4F5BD2B-E9F6-4CDE-BB7F-000EBC074DC1/PPHM_News_2016_9_27_Peregrine_News_Releases.pdf

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote